Fresenius Medical Care AG & Co. KGaA (FMS)

DE — Healthcare Sector

Peers: DVA SGRY ACHC ENSG FSNUY SNN UHS GRFS MD

Automate Your Wheel Strategy on FMS

With Tiblio's Option Bot, you can configure your own wheel strategy including FMS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol FMS
Rev/Share 33.2607
Book/Share 24.4141
PB 0.9913
Debt/Equity 0.8307
CurrentRatio 1.4373
ROIC 0.0395

MktCap 13155111003.5136
FreeCF/Share 3.9644
PFCF 5.6547
PE 20.0403
Debt/Assets 0.3523
DivYield 0.0299
ROE 0.047

Rating B+
Score 3
Recommendation Neutral
P/E Score 2
DCF Score 4
P/B Score 4
D/E Score 1

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
Downgrade	FMS	UBS	Neutral	Sell	--	--	Sept. 2, 2025

News

Fresenius Medical Care delivers 18% earnings growth in 2024 and continues the acceleration momentum into 2025

FMS
Published: February 25, 2025 by: PRNewsWire
Sentiment: Neutral

Organic revenue growth1 of 4% driven by Care Enablement and Care Delivery Underlying U.S. same market treatment growth further accelerated in Q4 and turned positive for the full year Accumulated savings of the FME25 program already reached EUR 567 million and 2025 target raised to EUR 750 million With 18% operating income2 growth top end of the 2024 outlook range reached Reported operating income grew by 2%, reported net income3 by +8% Net financial leverage ratio reduced from 3.2x to 2.9x and dividend is planned to be raised by 21% High teens to high twenties percent earnings growth in 2025, …

image for news Fresenius Medical Care delivers 18% earnings growth in 2024 and continues the acceleration momentum into 2025

Fresenius Medical Care slightly beats market estimates in fourth quarter

FMS
Published: February 25, 2025 by: Reuters
Sentiment: Positive

Fresenius Medical Care , the world's largest dialysis specialist, reported fourth quarter results slightly above market expectations on Tuesday, citing positive development both in its care delivery and care enablement segments.

image for news Fresenius Medical Care slightly beats market estimates in fourth quarter

Fresenius Medical Care Announces Divestment of Select Laboratory Assets to Quest Diagnostics

DGX, FMS
Published: February 24, 2025 by: PRNewsWire
Sentiment: Neutral

Quest to provide comprehensive dialysis-related laboratory and water testing services to Fresenius Medical Care owned and affiliated clinics in the United States BAD HOMBURG, Germany and SECAUCUS, N.J. , Feb. 24, 2025 /PRNewswire/ -- Fresenius Medical Care (XETRA: FME; NYSE: FMS), the world's leading provider of products and services for individuals with renal disease, and Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that, under terms of a definitive acquisition agreement, Quest will acquire select assets of FME's wholly owned Spectra Laboratories, a leading provider of renal-specific laboratory testing services in the U.S. In addition, …

image for news Fresenius Medical Care Announces Divestment of Select Laboratory Assets to Quest Diagnostics

1
2
3 (current)

About Fresenius Medical Care AG & Co. KGaA (FMS)

IPO Date 1996-09-17
Website https://www.freseniusmedicalcare.com
Industry Medical - Care Facilities
CEO Helen Giza
Employees 112035

Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, it operated 4,171 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.